Coherus BioSciences, Inc.

NasdaqGM:CHRS Stock Report

Market Cap: US$129.8m

Coherus BioSciences Past Earnings Performance

Past criteria checks 2/6

Coherus BioSciences's earnings have been declining at an average annual rate of -26.3%, while the Biotechs industry saw earnings growing at 20.4% annually. Revenues have been declining at an average rate of 14.4% per year.

Key information

-26.3%

Earnings growth rate

-26.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-14.4%
Return on equityn/a
Net Margin10.7%
Last Earnings Update31 Dec 2024

Recent past performance updates

Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings

Mar 24
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings

Recent updates

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 17
author-image

UDENYCA Divestiture And LOQTORZI Progress Will Forge Opportunity Amid Risks

Apr 03 UDENYCA divestiture and headcount reduction will strengthen the balance sheet and improve margins through reduced expenses.

Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop

Mar 28
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop

Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings

Mar 24
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise

Dec 21
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Revenue & Expenses Breakdown

How Coherus BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:CHRS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 242672915093
30 Sep 24304016395
30 Jun 24308-29172102
31 Mar 24302-59186100
31 Dec 23257-238186106
30 Sep 23211-217192112
30 Jun 23182-264193129
31 Mar 23183-271195151
31 Dec 22211-292198199
30 Sep 22239-279195221
30 Jun 22276-230190229
31 Mar 22304-210179246
31 Dec 21327-287170363
30 Sep 21364-232157357
30 Jun 21395-165149342
31 Mar 21443-76143310
31 Dec 20476132139143
30 Sep 20489162137192
30 Jun 20487181137153
31 Mar 20435145140127
31 Dec 193569013794
30 Sep 19232-121350
30 Jun 19121-1181280
31 Mar 1937-1851100
31 Dec 180-20994106
30 Sep 180-196750
30 Jun 180-196640
31 Mar 181-208670
31 Dec 172-238690
30 Sep 172-265690
30 Jun 17165-122690
31 Mar 17178-137590
31 Dec 16190-127520
30 Sep 16199-104470
30 Jun 1644-259440
31 Mar 1637-248410
31 Dec 1530-223360
30 Sep 1526-200300
30 Jun 1535-137240
31 Mar 1533-103190
31 Dec 1431-87160
30 Sep 1426-73140
30 Jun 1410-86120

Quality Earnings: CHRS has a high level of non-cash earnings.

Growing Profit Margin: CHRS became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CHRS has become profitable over the past 5 years, growing earnings by -26.3% per year.

Accelerating Growth: CHRS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CHRS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (40.2%).

Return on Equity

High ROE: CHRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/19 02:25
End of Day Share Price 2025/04/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coherus BioSciences, Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Balaji PrasadBarclays
Balaji PrasadBarclays